FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study

FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study

Abstract Background Fluorouracil, leucovorin (5FU/LV), and nanoliposomal-irinotecan (nal-IRI) combination therapy has been established as the second-line treatment for advanced pancreatic ductal adenocarcinoma. Oxaliplatin with 5FU/LV (FOLFOX) is often used as a subsequent treatment, although its ef...

Full description

Bibliographic Details
Main Authors: Satoshi Kobayashi, Shun Tezuka, Yui Yamachika, Shotaro Tsunoda, Shuhei Nagashima, Yuichiro Tozuka, Taito Fukushima, Manabu Morimoto, Makoto Ueno, Junji Furuse, Shin Maeda
Format: Article
Language:English
Published: BMC 2023-02-01
Series:BMC Cancer
Subjects:
Oxaliplatin
FOLFOX
Third-line treatment
Salvage
CRP
Homologous recombination deficiency
Online Access:https://doi.org/10.1186/s12885-023-10654-3

Internet

https://doi.org/10.1186/s12885-023-10654-3

Similar Items